默沙东完成收购Cidara Therapeutics

Core Viewpoint - Merck & Co. has successfully completed a cash tender offer for all outstanding common shares of Cidara Therapeutics, with a total transaction value of approximately $9.2 billion [1] Group 1 - The acquisition agreement was finalized in November 2025, where Merck agreed to acquire Cidara at a price of $221.50 per share in cash [1]